HENDERSON, Nev., Jan. 09, 2018 (GLOBE NEWSWIRE) -- United Health Products, Inc. (UHP) (OTCPK:UEEC), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that the key patent underlying HemoStyp has been extended until 2029.
Separately, the company announced that it is continuing its work in the FDA’s CtQ Pilot program to have HemoStyp approved for Class III internal surgical use, as well as maintaining its Class II submission for expanded indication.
About United Health Products, Inc.
United Health Products (UHP) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UHP is focused on identifying new markets and applications for its products, and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.
For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
Company Contact:
United Health Products, Inc.
877-358-3444
IR Contact:
PAN Consultants Ltd.
Philippe Niemetz
212 -344 - 6464